Strategies in the design of antiviral drugs

@article{Clercq2002StrategiesIT,
  title={Strategies in the design of antiviral drugs},
  author={Erik De Clercq},
  journal={Nature Reviews Drug Discovery},
  year={2002},
  volume={1},
  pages={13-25}
}
Key PointsGreater understanding of viral life cycles has resulted in the discovery and validation of several targets for therapeutic intervention, and an increase in the number of antiviral drugs from 5 in 1990 to over 30 in 2001. However, there is considerable room for improvement, as these compounds are not always efficacious (owing to virus resistance) or well tolerated.Antiviral drug design could, in principle, be targeted at either viral proteins or cellular proteins. The first approach is… CONTINUE READING
BETA

Figures, Tables, and Topics from this paper.

Citations

Publications citing this paper.
SHOWING 1-10 OF 15 CITATIONS

Varicella zoster virus infection

  • Nature Reviews Disease Primers
  • 2015

The design of drugs for HIV and HCV

  • Nature Reviews Drug Discovery
  • 2007

A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance.

  • Proceedings of the National Academy of Sciences of the United States of America
  • 2005

References

Publications referenced by this paper.
SHOWING 1-10 OF 109 REFERENCES

Antiviral drugs: current state of the art.

  • Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology
  • 2001

Comparison of the anti-influenza virus activity of RWJ-270201 with those of oseltamivir and zanamivir

S Bantia
  • Antimicrob. Agents Chemother
  • 2001

Similar Papers

Loading similar papers…